alpha-MSH analogue comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-10-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Alpha-MSH analogue with a lactam ring |
| Molecular formula | C50H69N15O9 | Commonly cited value for the neutral peptide |
| Molecular weight | 1024.18 g/mol | Calculated for the free molecule |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water, DMSO and ethanol | Dissolution in pure water is often slow |
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
While BIA Separations was the first to commercially market polymeric monoliths, Merck KGaA was the first company to market silica monoliths. In 1996, Tanaka and coworkers at the Kyoto Institute of Technology published extensive work on silica monolith technologies. Merck was later issued a license from Kyoto Institute of Technology to develop and produce the silica monoliths. Promptly thereafter, in 2001, Merck introduced its Chromolith line of monolithic HPLC columns at analytical instrumentation trade show PittCon. Initially, says Karin Cabrera, senior scientist at Merck, the high flow rate was the selling point for the Chromolith line. Based on customer feedback, though, Merck soon learned that the columns were more stable and longer-lived than particle-packed columns. The columns were the recipients of various new product awards. Difficulties in production of the silica monoliths and tight patent protection have precluded attempts by other companies at developing a similar product. It has been noted that there are more patents concerning how to encapsulate the silica rod than there are on the manufacture of the silica itself. Historically, Merck has been known for its superior chemical products, and, in liquid chromatography, for the purity and reliability of its particulate silica. Merck is not known for its LC columns. Five years after the introduction of its Chromolith line, Merck made a very strategic marketing decision.
Produced by Charles Konowal, directed by Stephen Low, made by Uden Associates and National Film Board of Canada 27 August Little by Little, about Eric Drexler and nanotechnology. Produced by David Kennard, directed by Karl Sabbagh, made by InCA 3 September Woomera, a rocket base for over 30 years; set up by Sir John Events; rockets arrived in 1949, and the Australian Security Intelligence Organisation (ASIO) needed to be set up as sensitive information had leaked to the Soviets; the Weapons Research Establishment was set up at Edinburgh, South Australia, which is now largely RAAF Base Edinburgh; the GAF Jindivik target drone was developed in 1952; up to 6 or 7 guided missiles would be launched per day; the Malkara and Stanley Schatzel (1924-2015), technical director from 1970 to 1989 for Hawker Siddeley Dynamics; the drop of the Blue Danube by No.
=== Equilibrium thermodynamics === When formed or re-equilibrated in reversible reactions, methane molecules can exchange isotopes with each other or with other substances present, such as H2O, H2 and CO2, and reach internal isotopic equilibrium. As a result, clumped isotopologues are enriched relative to the stochastic distribution.
Giant was founded in 1944 as a small grocery store in Kuala Lumpur and expanded with the opening of the Teng Minimarket Centre (TMC) in Bangsar in 1974. In 1999, Dairy Farm International Holdings bought a 90% interest in the chain, with the Teng family retaining the balance. By 2003, the holding company for the chain had changed its name to Dairy Farm Giant Retail Sdn Bhd, and the chain had eight Giant hypermarkets and 10 supermarkets as well as three Cold Storage supermarkets. Later, the company operated as a subsidiary of Dairy Farm International Holdings Limited and the name was changed to GCH Retail (Malaysia) Sdn Bhd. GCH Retail was 30%-owned by Syarikat Pesaka Antah Sdn Bhd — a company controlled by the Negeri Sembilan royal family and balance 70% by DFI Mauritius Ltd. In December 2011, Giant expanded into Vietnam. However, in February 2018, the Group disposed of its 100% interest in Asia Investment Supermarket Trading Co. Ltd. (AISTC), operating a hypermarket in Vietnam to Auchan Retail Vietnam, for net cash inflow of US$6.4 million. As such, the Group has exited from supermarket and hypermarket business in Vietnam. Beginning 2017, Giant and its peers in the hypermarket retail segment in Malaysia had been underperforming due to high operational costs, weakening consumer spending, and stiffer competition from smaller supermarkets, retailers and e-commerce. In 2019, it closed at least six outlets in Peninsular Malaysia operations. It comprises 2 hypermarkets and 2 Cold Storage outlets in Selangor, 1 each in Kedah, Perak, and Kuala Lumpur.
Sources: en.wikipedia.org
== Division of Scientific Education and Professional Development == The Division of Scientific Education and Professional Development (DSEPD) provides leadership for recruiting, training, developing and retaining the nation's public health workforce at all levels of the public health system.
== Genetics == Contrary to bacteria and fungi, most plant metabolic pathways are not grouped into biosynthetic gene clusters, but instead are scattered as individual genes. Some exceptions have been discovered: steroidal glycoalkaloids in Solanum, polyketides in Pooideae, benzoxazinoids in Zea mays, triterpenes in Avena sativa, Cucurbitaceae, Arabidopsis, and momilactone diterpenes in Oryza sativa.
=== Non-destructive sampling protocols === Although the ammonium bicarbonate protocol should not be considered a non-destructive method, it was followed by more 'true' non-destructive methods. The first of these was the eraser protocol, first tested on parchment, but later also applied to bone. The eraser protocol is performed by rubbing a PVC eraser on a piece of parchment or bone. The friction generates triboelectric forces, which causes small particles of the sample to cling to the eraser waste. From the eraser waste collagen can then be extracted and analysed. The eraser protocol was found to work relatively well for parchment, but it is less effective on bone. Additionally, it leaves microscopic traces on the bone surface, which appear very similar to use wear traces and could be an issue for use wear analysis. A second non-destructive protocol is the plastic bag protocol, first published in 2019. It is based on the idea that the normal friction between an object and the plastic bags, commonly used for storing archaeological objects, might be sufficient to extract enough material for ZooMS analysis. A third protocol uses the same triboelectric principle. However, instead of using an eraser, this microgrid protocol employs a fine polishing film to remove very small amounts of material from a sample. The last non-destructive protocol that has been published for ZooMS is the membrane box protocol. The membrane box protocol is based on contact electrification, which is the generation of electrostatic forces due to small localised differences in charge between two objects.
After incubation, the enrichment broth can also be subcultured to granada medium agar where GBS grows as pink-red colonies or to chromogenic agars, where GBS grows as colored colonies. GBS-like colonies that develop in chromogenic media should be confirmed as GBS using additional reliable tests to avoid misidentification. Nucleic acid amplification tests (NAAT) such as polymerase chain reaction (PCR) and DNA hybridization probes have been developed for identifying GBS directly from recto-vaginal samples, but they have a high false negative rate and still cannot replace antenatal culture for the most accurate detection of GBS carriers. This technology to detect GBS must be improved and simplified to make the method cost-effective and useful as a point-of-care test. Nevertheless, these tests can also be used to detect GBS directly from broth media, after the enrichment step, avoiding the subculture of the incubated enrichment broth to an appropriate agar plate.
=== Cold War === The Soviet biological weapons program began a program focusing on botulinum toxin from 1951 at the Ministry of Defence's Scientific-Research Institute of Hygiene in Sverdlovsk Oblast. The United States biological weapons program possessed botulinum toxin before it was disbanded in 1969. The Iraqi biological weapons program began developing botulinum toxin at its Al Hakum production plant from 1989, the basis for which it originally received among a range of agents from the American Type Culture Collection in 1988.
Sources: en.wikipedia.org
=== Impact on negotiations of extraditing suspects to Singapore === In 2002, Singapore tried to negotiate with Australia for the extradition of a British murder suspect and fugitive Michael McCrea, who was wanted for the double murder of a couple whose corpses were discovered abandoned in a car at Orchard Towers. However, McCrea, who was arrested in Australia, was not extradited as Australia, which abolished the death penalty for all offences by then, was not legally allowed to extradite suspects back to countries where they would face the death sentence. It was only after Singapore gave the Australian government the assurance that McCrea would not be hanged even if he was convicted of murder, which allowed McCrea to be sent back to Singapore for trial. McCrea was eventually convicted of culpable homicide and destroying evidence of a murder case, and sentenced to a total of 24 years in jail. This left an impact and precedent on Singapore's avenues to successfully negotiating for extradition of suspects from countries where the death penalty or caning was not practised, including the extradition of suspected bank robber David James Roach, whom the Singapore government promised would not face caning for robbery. Roach was eventually sent back to Singapore, where he later served five years in prison, and he was pardoned from caning by President Halimah Yacob.
== Other uses == lh (digraph), in many languages Bristol LH, a type of British bus manufactured between 1967 and 1982 Chrysler LH platform, a type of Chrysler car made from 1993 through 2004 Late Helladic, a period in the history of ancient Greece, during the Bronze Age Leasehold, or tenure, in property law Left-handed, or left hand Letterhead, a heading at the top of a sheet of letter paper Lewis Hamilton (born 1985), British racing driver
AL amyloidosis occurs in about 3–13 per million people per year and AA amyloidosis in about two per million people per year. The usual age of onset of these two types is 55 to 60 years old. Without treatment, life expectancy is between six months and four years. In the developed world about one per 1,000 deaths are from systemic amyloidosis. Amyloidosis has been described since at least 1639.
Mianserin appears to exert its effects via antagonism of histamine and serotonin receptors, and inhibition of norepinephrine reuptake. More specifically, it is an antagonist/inverse agonist at most, if not all sites of the histamine H1 receptor, serotonin 5-HT1D, 5-HT1F, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT3, 5-HT6, and 5-HT7 receptors, and adrenergic α1- and α2-adrenergic receptors, and additionally a norepinephrine reuptake inhibitor. As an H1 receptor inverse agonist with high affinity, mianserin has strong antihistamine effects (e.g., sedation). Conversely, it has low affinity for the muscarinic acetylcholine receptors, and hence lacks anticholinergic properties. Mianserin has been found to be a low affinity but potentially significant partial agonist of the κ-opioid receptor (Ki = 1.7 μM; EC50 = 0.53 μM), similarly to some tricyclic antidepressants (TCAs). Blockade of the H1 and possibly α1-adrenergic receptors has sedative effects, and also antagonism of the 5-HT2A and α1-adrenergic receptors inhibits activation of intracellular phospholipase C (PLC), which seems to be a common target for several different classes of antidepressants. By antagonizing the somatodendritic and presynaptic α2-adrenergic receptors, which function predominantly as inhibitory autoreceptors and heteroreceptors, mianserin disinhibits the release of norepinephrine, dopamine, serotonin, and acetylcholine in various areas of the brain and body.
== History == Inotuzumab ozogamicin was discovered by scientists collaborating at Celltech and Wyeth, and it was developed by Pfizer which had acquired Wyeth. Celltech and Wyeth entered into a collaboration in 1991 to develop antibody-drug conjugates. The humanized antibody portion was generated at Celltech and the DNA encoding it was transfected into CHO cells, which were sent to Wyeth, where chemists expressed and purified the antibodies and conjugated them with the linker to the cytotoxin; the work was published in 2004. Celltech was acquired by UCB in 2004 and Wyeth was acquired by Pfizer in 2009. In May 2013, a phase III trial in participants with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma (NHL) who were not candidates for intensive high-dose chemotherapy was terminated for futility. In March 2024, the FDA approved inotuzumab ozogamicin for the treatment of children aged one year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia. Efficacy was evaluated in a multicenter, single-arm, open-label study in 53 pediatric participants aged one year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia. Two dose levels were evaluated--an initial dose of 1.4 mg/m2/cycle in 12 participants and 1.8 mg/m2/cycle in 41 participants. Premedications included methylprednisolone 1 mg/kg (maximum of 50 mg), an antipyretic, and an antihistamine. Participants received a median of 2 cycles of therapy (range: 1 to 4 cycles).
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.
No national medicines agency has approved melanotan-2 for clinical use. Afamelanotide, a related but distinct peptide, holds a marketing authorisation in the European Union for a rare photosensitivity disorder. Melanotan-2 itself is handled as a laboratory chemical.
Its broad activity across melanocortin receptors makes it a tool for probing pigmentation, appetite and vascular signalling. Early trials recorded skin darkening and other effects that were not the original focus of the work. Those observations generated hypotheses that later studies have examined.
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.